FLT3 and acute myeloid leukemia: The approval granted by the European Medicines Agency (EMA) included single-agent maintenance therapy for FLT3-mutated AML patients in CR and although the studied patient population was younger than 60 years, both agencies approved midostaurin without an upper age limit.